Analyzing the Data for Entrectinib in ROS1 TKI-Naive Patients With NSCLC
June 6th 2019Alexander Drilon, MD, clinical director, Early Drug Development Service, and associate professor of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the data examining the role of entrectinib in patients with non–small cell lung cancer who are naïve to treatment with a ROS1 tyrosine kinase inhibitor.
Watch
Multidisciplinary Approach Helps Determine Best Setting for Surgery in Metastatic Breast Cancer
June 5th 2019Ross Mudgway, BS, explains how a multidisciplinary approach as well as open discussions with the patient can help determine the best course of action for patients with metastatic breast cancer.
Watch
Overall Survival Update From COLUMBUS Trial in BRAF V600-Mutant Melanoma
June 4th 2019Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, shares updated overall survival data from the phase III COLUMBUS trial examining encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Watch
Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer
June 4th 2019Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Watch
Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC
June 3rd 2019Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Watch
Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC
June 2nd 2019Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer.
Watch
Highlighting Key Trials in Kidney Cancer
June 1st 2019Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.
Watch
Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC
May 24th 2019Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.
Watch